AU2003226927A8 - Novel carboxamide compounds for use in mch receptor related disorders - Google Patents

Novel carboxamide compounds for use in mch receptor related disorders

Info

Publication number
AU2003226927A8
AU2003226927A8 AU2003226927A AU2003226927A AU2003226927A8 AU 2003226927 A8 AU2003226927 A8 AU 2003226927A8 AU 2003226927 A AU2003226927 A AU 2003226927A AU 2003226927 A AU2003226927 A AU 2003226927A AU 2003226927 A8 AU2003226927 A8 AU 2003226927A8
Authority
AU
Australia
Prior art keywords
related disorders
receptor related
carboxamide compounds
mch receptor
novel carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003226927A
Other versions
AU2003226927A1 (en
Inventor
Trond Ulven
Christian E Elling
Pia Karina Norregaard
Thomas Hogberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7TM Pharma AS
Original Assignee
7TM Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7TM Pharma AS filed Critical 7TM Pharma AS
Publication of AU2003226927A8 publication Critical patent/AU2003226927A8/en
Publication of AU2003226927A1 publication Critical patent/AU2003226927A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
AU2003226927A 2002-04-09 2003-04-08 Novel carboxamide compounds for use in mch receptor related disorders Abandoned AU2003226927A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200200518 2002-04-09
DKPA200200518 2002-04-09
DKPA200200757 2002-05-16
DKPA200200757 2002-05-16
PCT/DK2003/000232 WO2003087044A2 (en) 2002-04-09 2003-04-08 Novel carboxamide compounds for use in mch receptor related disorders

Publications (2)

Publication Number Publication Date
AU2003226927A8 true AU2003226927A8 (en) 2003-10-27
AU2003226927A1 AU2003226927A1 (en) 2003-10-27

Family

ID=29252083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003226927A Abandoned AU2003226927A1 (en) 2002-04-09 2003-04-08 Novel carboxamide compounds for use in mch receptor related disorders

Country Status (2)

Country Link
AU (1) AU2003226927A1 (en)
WO (1) WO2003087044A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045313A2 (en) 2001-11-27 2003-06-05 Merck & Co. Inc. 2-aminoquinoline compounds
CA2515717A1 (en) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US20050256161A1 (en) * 2003-08-13 2005-11-17 Tempest Paul A Melanin concentrating hormone receptor antagonists
CA2533112A1 (en) 2003-08-13 2005-03-03 Christopher Hulme Melanin concentrating hormone receptor antagonist
DE102004003812A1 (en) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7262318B2 (en) 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
GB0416728D0 (en) * 2004-07-27 2004-09-01 7Tm Pharma As Medicinal use of receptor ligands
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
DE102004039789A1 (en) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
SG177221A1 (en) 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
TWI417100B (en) 2007-06-07 2013-12-01 Astrazeneca Ab Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009082398A1 (en) 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
AR075402A1 (en) 2009-02-13 2011-03-30 Sanofi Aventis OXYGENATE AND / OR NITROGEN HETEROCICLIC DERIVATIVES OF TETRAHYDRONAFTALENE, DRUGS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF METABOLIC DISORDERS, SUCH AS OBESITY, AMONG OTHERS.
TW201040154A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
EA021437B1 (en) 2009-09-29 2015-06-30 Глэксо Груп Лимитед Compounds inhibiting lrrk2 kinase activity
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
JP2017533187A (en) 2014-09-25 2017-11-09 ユニヴァーシティー オブ ノートル ダム デュ ラック Non-β-lactam antibiotics
TW201811766A (en) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection
CN113651805B (en) * 2021-07-19 2023-07-25 安徽医科大学 1,2, 4-oxadiazole-pyridine compound and application thereof in treating Alzheimer's disease
CN113754646B (en) * 2021-07-19 2023-07-25 安徽医科大学 (4- (1, 2, 4-oxadiazol-5-yl) phenyl) carboxamide derivatives and application thereof in anti-arthritis drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
WO2003087044A3 (en) 2004-11-04
AU2003226927A1 (en) 2003-10-27
WO2003087044A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AU2003226927A8 (en) Novel carboxamide compounds for use in mch receptor related disorders
AU2003287880A8 (en) Cyclic quinoline compounds for use in mch receptor related disorders
HUE039348T2 (en) A2A receptor antagonists for use in the treatment of movement disorders
PL373656A1 (en) Substituted amides
EP1575901A4 (en) Substituted amides
IL177057A0 (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
EP1814550A4 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
IL177058A0 (en) Polyheterocycilic compounds and their use as metabotropic glutamate receptor antagonists
TW572533U (en) Adjusting apparatus
PL374674A1 (en) Mchir antagonists
GB0206793D0 (en) Alertness bar
IL173746A0 (en) Modified il-4 mutein receptor antagonists
GB2386062B (en) Adjustable bed
AU2003226928A1 (en) Novel aminotetraline compounds for use in mch receptor related disorders
IL164697A0 (en) N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
PL378753A1 (en) Ccr-3 receptor antagonists
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
AU2003226929A1 (en) Novel benzamide compounds for use in mch receptor related disorders
GB2392618B (en) Compositions for therapeutic use
IL173337A0 (en) Receptor
GB0226227D0 (en) Receptors
SG131946A1 (en) Ccr3 receptor antagonists
GB0326059D0 (en) Head mounted timer
GB0223399D0 (en) Receptors
AU2003262923A8 (en) Genes involved in neuropsychiatric disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase